Serum levels of interleukin-22 and hepatitis B core-related antigen are associated with treatment response to entecavir therapy in chronic hepatitis B

Hepatology Research

Volumn 44, Issue 10, 2014, Pages E172-E180

  Okuhara, Sadahisa ^a   Umemura, Takeji ^a   Joshita, Satoru ^a   Shibata, Soichiro ^a   Kimura, Takefumi ^a   Morita, Susumu ^a   Komatsu, Michiharu ^a   Matsumoto, Akihiro ^a   Yoshizawa, Kaname ^a   Katsuyama, Yoshihiko ^c   Ota, Masao ^b   Tanaka, Eiji ^a  

^a Department of Medicine Division of Hepatology and Gastroenterology   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SHINSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Entecavir; Hepatitis B core related antigen; Hepatitis B surface antigen; Hepatitis B virus; Interleukin 22

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; ENTECAVIR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; VIRUS DNA;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS B; CLINICAL ARTICLE; CONTROLLED STUDY; CXCL11 CHEMOKINE BLOOD LEVEL; CXCL9 CHEMOKINE BLOOD LEVEL; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GAMMA INTERFERON INDUCIBLE PROTEIN 10 BLOOD LEVEL; HUMAN; HUMAN CELL; INTERLEUKIN 12P70 BLOOD LEVEL; INTERLEUKIN 2 BLOOD LEVEL; INTERLEUKIN 21 BLOOD LEVEL; INTERLEUKIN 22 BLOOD LEVEL; INTERLEUKIN 6 BLOOD LEVEL; LONGITUDINAL STUDY; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA BLOOD LEVEL; MALE; MONOCYTE CHEMOTACTIC PROTEIN 1 BLOOD LEVEL; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

EID: 84907880114     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12287     Document Type: Article

References (39)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745.
2. Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol 2009; 44 (Suppl 19): 102-107.
3. Chen CJ, Yang HI, Su J etal. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
4. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686.
5. Dienstag JL, Goldin RD, Heathcote EJ etal. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105-117.
6. Liaw YF, Sung JJ, Chow WC etal. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531.
7. Hosaka T, Suzuki F, Kobayashi M etal. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58: 98-107.
8. Yoneda S, Umemura T, Katsuyama Y etal. Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients. J Infect Dis 2011; 203: 1087-1095.
9. Yoneda S, Umemura T, Joshita S etal. Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic hepatitis C. Hepatol Res 2011; 41: 587-593.
10. Umemura T, Joshita S, Yoneda S etal. Serum interleukin (IL)-10 and IL-12 levels and IL28B gene polymorphisms: pretreatment prediction of treatment failure in chronic hepatitis C. Antivir Ther 2011; 16: 1073-1080.
11. Wu JF, Wu TC, Chen CH etal. Serum levels of interleukin-10 and interleukin-12 predict early, spontaneous hepatitis B virus e antigen seroconversion. Gastroenterology 2010; 138: 165-172 e-13.
12. Tan AT, Koh S, Goh W etal. A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. J Hepatol 2010; 52: 330-339.
13. Publicover J, Goodsell A, Nishimura S etal. IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. J Clin Invest 2011; 121: 1154-1162.
14. Zhang Y, Cobleigh MA, Lian JQ etal. A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus. Gastroenterology 2011; 141: 1897-1906.
15. Ma SW, Huang X, Li YY etal. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B. J Hepatol 2012; 56: 775-781.
16. Tacke F, Zimmermann HW, Berres ML, Trautwein C, Wasmuth HE. Serum chemokine receptor CXCR3 ligands are associated with progression, organ dysfunction and complications of chronic liver diseases. Liver Int 2011; 31: 840-849.
17. Feng D, Kong X, Weng H etal. Interleukin-22 promotes proliferation of liver stem/progenitor cells in mice and patients with chronic hepatitis B virus infection. Gastroenterology 2012; 143: 188-98 e7.
18. Pan CJ, Wu HL, Kuo SF etal. Serum interleukin 6 level correlates with outcomes of acute exacerbation of chronic hepatitis B. Hepatol Int 2012; 6: 591-597.
19. Umemura T, Tanaka E, Kiyosawa K, Kumada H. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis 2008; 47: e52-56.
20. Umemura T, Zen Y, Hamano H, Kawa S, Nakanuma Y, Kiyosawa K. Immunoglobin G4-hepatopathy: association of immunoglobin G4-bearing plasma cells in liver with autoimmune pancreatitis. Hepatology 2007; 46: 463-471.
21. Kao JT, Lai HC, Tsai SM etal. Rather than interleukin-27, interleukin-6 expresses positive correlation with liver severity in naive hepatitis B infection patients. Liver Int 2012; 32: 928-936.
22. Zeremski M, Petrovic LM, Talal AH. The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection. J Viral Hepat 2007; 14: 675-687.
23. Heydtmann M, Adams DH. Chemokines in the immunopathogenesis of hepatitis C infection. Hepatology 2009; 49: 676-688.
24. Zeremski M, Petrovic LM, Chiriboga L etal. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 2008; 48: 1440-1450.
25. Zeremski M, Hooker G, Shu MA etal. Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection. J Hepatol 2011; 55: 545-553.
26. Colonna M. Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity. Immunity 2009; 31: 15-23.
27. Zenewicz LA, Flavell RA. Recent advances in IL-22 biology. Int Immunol 2011; 23: 159-163.
28. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Flavell RA. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 2007; 27: 647-659.
29. Ki SH, Park O, Zheng M etal. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology 2010; 52: 1291-1300.
30. Park O, Wang H, Weng H etal. In vivo consequences of liver-specific interleukin-22 expression in mice: implications for human liver disease progression. Hepatology 2011; 54: 252-261.
31. Kong X, Feng D, Wang H etal. Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology 2012; 56: 1150-1159.
32. Meng F, Wang K, Aoyama T etal. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 2012; 143: 765-776 e1-3.
33. Jiang R, Tan Z, Deng L etal. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 2011; 54: 900-909.
34. Zhang JY, Zhang Z, Lin F etal. Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 2010; 51: 81-91.
35. Kimura T, Ohno N, Terada N etal. Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain. J Biol Chem 2005; 280: 21713-21719.
36. Kimura T, Rokuhara A, Sakamoto Y etal. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol 2002; 40: 439-445.
37. Lee JM, Ahn SH, Kim HS etal. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology 2011; 53: 1486-1493.
38. Liaw YF. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology 2011; 54: E1-9.
39. Reijnders JG, Rijckborst V, Sonneveld MJ etal. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 2011; 54: 449-454.